Proteostasis pulls stock offering following Kerrisdale short report; Cidara issues supplemental PhII rezafungin data
→ Hours after the company came under assault by the hit squad at Kerrisdale Capital, Proteostasis Therapeutics $PTI yanked a planned offering of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
